Status:
COMPLETED
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
Lead Sponsor:
Radboud University Medical Center
Conditions:
Ischemia-Reperfusion Injury
Atherosclerosis
Eligibility:
MALE
18-50 years
Phase:
PHASE4
Brief Summary
This study is performed to determine whether a seven day treatment with dipyridamole (slow release, 200mg twice daily) can induce a protective effect against ischemia-reperfusion injury, after ischemi...
Detailed Description
Rationale: Dipyridamole increases the endogenous adenosine level by inhibition of the nucleoside transporter (ENT-1). Activation of the adenosine receptor protects against ischemia-reperfusion injury...
Eligibility Criteria
Inclusion
- Male
- age between 18-50yr.
Exclusion
- cardiovascular disease
- hypertension (systole \> 140 mmHg, diastole \> 90 mmHg)
- hypercholesterolemia (fasting total cholesterol \> 5.5 mmol/l or not fasting total cholesterol \> 6.5mmol/L)
- diabetes mellitus (fasting glucose \> 7.0 mmol/L or random glucose \> 11.0 mmol/L)
- asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
- participation in any clinical trial during the last 60 days prior to this study.
- administration of any radioactivity for research purposes during the last 5 years prior to this study.
- concomitant medication
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00457405
Start Date
June 1 2007
End Date
March 1 2008
Last Update
April 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB